The EdiThal trial reported successful engraftment and significant increases in total hemoglobin (Hb) and fetal hemoglobin (HbF) levels in patients with TDT. Can you elaborate on the clinical implications of these findings for patients?

How does the increase in Hb and HbF levels observed in the trial compare to current treatment options for TDT, and what advantages might reni-cel offer to patients?

All seven patients in the trial achieved transfusion independence for up to 9.9 months post-reni-cel infusion. How significant is this outcome in the context of managing TDT, and what does it suggest about the long-term efficacy of reni-cel?

The safety profile of reni-cel was reported to be consistent with myeloablative conditioning with busulfan, with no treatment-related adverse events. How does this safety profile impact the potential adoption of reni-cel as a treatment for TDT?

The trial utilized AsCas12a for gene editing. Can you discuss the advantages of this specific gene editing nuclease and its role in the efficacy and safety observed in the EdiThal trial?

Patients showed a mean total Hb of 12.8 g/dL by Month 6 and a mean HbF concentration of 8.9 g/dL by Month 3. How do these levels correlate with clinical benefits, such as reduced complications and improved quality of life for TDT patients?

The EdiThal trial included patients aged 18–35 years with a high transfusion burden prior to treatment. How might these results influence future studies and the potential expansion of reni-cel to a broader patient population?

With these promising interim results, what are the next steps for the EdiThal trial and the potential regulatory pathway for reni-cel? How might these developments impact the treatment landscape for beta-thalassemia?